Acute Lymphocytic Leukemia Pipeline Insight | Key Companies – PersonGen BioTherapeutics, Novartis, Jazz Pharma, Takara Bio, Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy, and Others
DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight 2023” report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including Acute Lymphocytic Leukemia clinical trials and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report
- DelveInsight’s Acute Lymphocytic Leukemia pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
- The leading Acute Lymphocytic Leukemia Companies include PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Life technology Co. Ltd., Celgene, and others
- Promising Acute Lymphocytic Leukemia Pipeline Therapies include Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others.
- The Acute Lymphocytic Leukemia companies and academics are working to assess challenges and seek opportunities that could influence Acute Lymphocytic Leukemia R&D. The Acute Lymphocytic Leukemia pipeline therapies under development are focused on novel approaches to treat/improve Acute Lymphocytic Leukemia.
To explore more information on the latest breakthroughs in the Acute Lymphocytic Leukemia Pipeline treatment landscape of the report, click here @ Acute Lymphocytic Leukemia Pipeline Outlook
Acute Lymphocytic Leukemia Overview
Acute Lymphocytic Leukemia is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. “”Lymphocytic”” means it develops from early (immature) forms of lymphocytes, a type of white blood cell.
Acute Lymphocytic Leukemia Emerging Drugs Profile
- CPX-351: Jazz Pharmaceuticals
Vyxeos (cytarabine and daunorubicin) liposome for injection, or CPX-351, is an investigational product being evaluated for the treatment of AML and is a combination of cytarabine and daunorubicin encapsulated within a nano-scale liposome at a 5:1 molar ratio. It is currently in phase II stage of development for ALL.
- JZP-458: Jazz Pharmaceuticals
JZP-458 is being developed by Jazz Pharmaceuticals for the treatment of Acute Lymphoblastic Leukemia. It is currently in phase II/III stage of development.
- UCART22: Cellectis
UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL. It is currently in phase I stage of development.
- JZP-341: Jazz Pharmaceuticals
JZP-341 is being developed by Jazz Pharmaceuticals for the treatment of Acute Lymphoblastic Leukemia. It is currently in preclinical stage of development.
For further information, refer to the detailed Acute Lymphocytic Leukemia Unmet Needs, Mu Acute Lymphocytic Leukemia Market Drivers, and Acute Lymphocytic Leukemia Market Barriers, click here for Acute Lymphocytic Leukemia Ongoing Clinical Trial Analysis
Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment
There are approx. 150+ key companies are developing therapies for Acute Lymphocytic Leukemia (ALL). The companies which have their Acute Lymphocytic Leukemia (ALL) drug candidates in the most advanced stage, i.e. phase II/III include Jazz Pharmaceuticals and others
Acute Lymphocytic Leukemia Pipeline Segmentation
Phases
DelveInsight’s Report covers around 160+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Request a sample and discover the recent advances in Acute Lymphocytic Leukemia Ongoing Clinical Trial Analysis and Medications, click here @ Acute Lymphocytic Leukemia Treatment Landscape
Scope of the Acute Lymphocytic Leukemia Pipeline Report
- Coverage- Global
- Acute Lymphocytic Leukemia Companies- PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, and others
- Acute Lymphocytic Leukemia Pipeline Therapies- Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others.
- Acute Lymphocytic Leukemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Acute Lymphocytic Leukemia Market Drivers and Acute Lymphocytic Leukemia Market Barriers, click here @ Acute Lymphocytic Leukemia Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Acute Lymphocytic Leukemia (ALL): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Acute Lymphocytic Leukemia (ALL) – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Acute Lymphocytic Leukemia (ALL) Collaboration Deals
- Late Stage Products (Phase III and Phase II/III)
- JZP-458: Jazz Pharmaceuticals
- Mid Stage Products (Phase II)
- CPX-351: Jazz Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- UCART22: Cellectis
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- JZP-341: Jazz Pharmaceuticals
- Inactive Products
- Acute Lymphocytic Leukemia (ALL) Key Companies
- Acute Lymphocytic Leukemia (ALL) Key Products
- Acute Lymphocytic Leukemia (ALL)- Unmet Needs
- Acute Lymphocytic Leukemia (ALL)- Market Drivers and Barriers
- Acute Lymphocytic Leukemia (ALL)- Future Perspectives and Conclusion
- Acute Lymphocytic Leukemia (ALL) Analyst Views
- Acute Lymphocytic Leukemia (ALL) Key Companies
- Appendix
Got Queries? Find out the related information on Acute Lymphocytic Leukemia Mergers and acquisitions, Acute Lymphocytic Leukemia Licensing Activities @ Acute Lymphocytic Leukemia Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
